melanotan 2 pathways Benefits of Melanotan-II (MT-2) Structure of Melanotan II and

Daily routine: Morning: Topical GHK-Cu to scalp Evening: Topical GHK-Cu to scalp Every day: BPC-157 500mcg subcutaneous injection 3x per week: TB-500 2-5mg subcutaneous injection (maintenance dose) Bedtime: IGF-1 LR3 50-60mcg (4-6 week cycles with breaks) Additional: Weekly microneedling with GHK-Cu application immediately after Monthly progress photos and measurements Expected results: This is the most aggressive protocol

The three most common explicit genetic factors are: LDL receptor (LDLR), ApoB and PCSK9, among which the most common is the LDLR gene mutation, accounting for ~90%

Available from: 425

This means a significant proportion of patients with LS will not meet the criteria

The abovementioned example is potentially applicable to all human druggable proteins, that is, proteins that have been demonstrated to be able to bind a drug